PTSM: Pharmaceutical Technology Sourcing and Management, Dec 7, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Dec 7, 2011
Global Feature
Patent Reform and the Pharmaceutical Industry: From First-To-File To Post-Grant Review And Beyond
By Courtenay C. Brinckerhoff
The author discusses the major changes in US patent laws as a result of the recently signed patent-reform law and the implications for pharmaceutical companies.
APIs
Technical Perspective: Antibody Drug Conjugates
By Patricia Van Arnum
A podcast moderated by Patricia Van Arnum, executive editor of Pharmaceutical Technology.
Outsourcing
Biosimilars' Technology Needs
By Eric Langer
Biosimilar manufacturers need better expression systems and analytical tools to compete.
CSR and Sustainability Forum
Pharmaceutical Companies Target Green Manufacturing
A roundup of pharmaceutical companies' sustainability objectives and key projects.
World Health Organization Issues Progress Report on Combating HIV/AIDS
By Patricia Van Arnum
International efforts, including improving access to medicines, have contributed to stemming the rise of HIV/AIDS in the developing world.
CSR and Sustainability in the News
By Patricia Van Arnum
A roundup of developments in corporate social responsibility and sustainability from the bio/pharmaceutical industry, its suppliers, and other private and public organizations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here